38
Participants
Start Date
May 13, 2022
Primary Completion Date
January 30, 2026
Study Completion Date
January 30, 2026
combination of drugs (chemoradiation (capecitabine and radiation) + FOLFOXIRI (Oxaliplatin, leucovorin, irinotecan, and fluorouracil)
To evaluate the safety and preliminary efficacy of Preoperative ChemoRadiation and FOLFOXIRI To Escalate Complete Response for Rectal Cancer patients. receive the experimental combination of drugs (chemoradiation (capecitabine and radiation) + FOLFOXIRI (Oxaliplatin, leucovorin, irinotecan, and fluorouracil) and undergo laboratory tests and study procedures on specified days during the study period, complete end of study evaluations and tests, and participate in post-study follow up every three months for three to four years.
RECRUITING
RWJBarnabas Health - Monmouth Medical Center, Lakewood
RECRUITING
RWJBarnabas Health - Saint Barnabas Medical Center, Livingston, Livingston
RECRUITING
Rutgers, The State University of New Jersey, New Brunswick
RECRUITING
RWJBarnabas Health - Robert Wood Johnson University Hospital, Somerset, Somerset
RECRUITING
RWJBarnabas Health - Community Medical Center, Toms River
Rutgers, The State University of New Jersey
OTHER